DNA Chip Based Prognosis of Lung Cancer
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00973427
- Lead Sponsor
- Medical Prognosis Institute A/S
- Brief Summary
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
- A histological diagnosis of primary NSCLC stage Ia
- Surgical removal of the tumor
- Age between 18 and 75 years
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
- A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
- Adjuvant treatment with chemotherapy.
- Prior history of cancer in the past 5 years or breast cancer at any time.
- Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-related survival 5 years
- Secondary Outcome Measures
Name Time Method Time to progression 5 years
Trial Locations
- Locations (5)
University of Alabama
🇺🇸Birmingham, Alabama, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Aarhus University Hospital
🇩🇰Aarhus, Denmark
University of Copenhagen
🇩🇰Copenhagen, Denmark
Odense University Hospital
🇩🇰Odense, Denmark
University of Alabama🇺🇸Birmingham, Alabama, United States